Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Polo

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Diagnostics (Basel, Switzerland)|October 1, 2020
A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) PatientsFrancesco Cortiula, Giulia Pasello, Alessandro Follador, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patientsLaura Mezquita, Melinda Charrier, Laura Faivre, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
Clinical Lung Cancer|October 12, 2019
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyAlessandro Dal Maso, Martina Lorenzi, Elisa Roca, et al.
Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in <i>EGFR</i>-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Diagnostics (Basel, Switzerland)|October 1, 2020
A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) PatientsFrancesco Cortiula, Giulia Pasello, Alessandro Follador, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patientsLaura Mezquita, Melinda Charrier, Laura Faivre, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
Clinical Lung Cancer|October 12, 2019
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyAlessandro Dal Maso, Martina Lorenzi, Elisa Roca, et al.
Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in <i>EGFR</i>-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Pageof 3